Results 11 to 20 of about 5,690,964 (274)
Ca, 2021 This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer.
H. Sung +6 more
semanticscholar +1 more source
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2018 BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater ...
L. Gandhi +28 more
semanticscholar +1 more source
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
New England Journal of Medicine, 2015 BACKGROUND Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.
H. Borghaei +27 more
semanticscholar +1 more source
Pembrolizumab for the treatment of non-small-cell lung cancer.
New England Journal of Medicine, 2015 BACKGROUND We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study.
E. Garon +26 more
semanticscholar +1 more source
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2018 Background Osimertinib is an oral, third‐generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that selectively inhibits both EGFR‐TKI–sensitizing and EGFR T790M resistance mutations.
J. Soria +23 more
semanticscholar +1 more source
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
New England Journal of Medicine, 2020 BACKGROUND There are limited data from randomized trials regarding whether volume-based, low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among male former and current smokers.
H. D. de Koning +23 more
semanticscholar +1 more source
EGFR-TKI ADR Management Chinese Expert Consensus
Chinese Journal of Lung Cancer, 2019 ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
doaj +1 more source
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science, 2015 Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non–small cell lung cancers ...
N. Rizvi +23 more
semanticscholar +1 more source
Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors
Chinese Journal of Lung Cancer, 2020 Epigenetic modification is closely related to the occurrence and development of tumors. It mainly regulates gene function and expression level through DNA methylation, histone modification, regulation of non-coding RNA and chromatin structure ...
Pan WANG +10 more
doaj +1 more source
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
Frontiers in Oncology, 2021 The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis.
Dan Pu +8 more
doaj +1 more source